Your browser is no longer supported. Please, upgrade your browser.
Settings
ARDS [NASD]
Aridis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own33.04% Shs Outstand10.23M Perf Week-15.38%
Market Cap62.91M Forward P/E- EPS next Y-0.64 Insider Trans0.29% Shs Float7.53M Perf Month-33.11%
Income-23.70M PEG- EPS next Q-0.63 Inst Own13.10% Short Float0.34% Perf Quarter-20.60%
Sales1.00M P/S62.91 EPS this Y30.60% Inst Trans-2.63% Short Ratio0.18 Perf Half Y-24.89%
Book/sh-0.84 P/B- EPS next Y79.60% ROA-150.70% Target Price- Perf Year-28.67%
Cash/sh0.83 P/C5.99 EPS next 5Y- ROE274.00% 52W Range4.55 - 8.50 Perf YTD-18.45%
Dividend- P/FCF- EPS past 5Y-18.60% ROI280.00% 52W High-39.85% Beta-
Dividend %- Quick Ratio0.60 Sales past 5Y-19.00% Gross Margin- 52W Low12.37% ATR0.66
Employees33 Current Ratio0.60 Sales Q/Q- Oper. Margin- RSI (14)38.34 Volatility20.84% 11.84%
OptionableNo Debt/Eq- EPS Q/Q-5.60% Profit Margin- Rel Volume0.41 Prev Close4.95
ShortableYes LT Debt/Eq- EarningsMay 11 AMC Payout- Avg Volume146.06K Price5.11
Recom2.00 SMA20-14.95% SMA50-19.35% SMA200-22.07% Volume27,576 Change3.29%
Feb-19-20Initiated ROTH Capital Buy $18
Jul-26-21 08:30AM  
Jul-19-21 08:30AM  
Jul-13-21 12:22PM  
06:41AM  
Jul-12-21 04:05PM  
Jun-30-21 04:04AM  
Jun-09-21 09:21AM  
May-11-21 04:01PM  
Mar-30-21 05:49PM  
Mar-26-21 08:00AM  
Mar-08-21 07:30AM  
Feb-23-21 07:25AM  
07:21AM  
05:30AM  
Feb-16-21 11:56PM  
Nov-24-20 05:30AM  
Nov-20-20 04:05PM  
Oct-27-20 04:24PM  
Oct-19-20 08:30AM  
Oct-14-20 05:30AM  
Sep-08-20 05:30AM  
Sep-04-20 01:32PM  
Aug-11-20 04:05PM  
Jul-15-20 08:42AM  
Jun-26-20 05:30AM  
Jun-22-20 05:30AM  
Jun-18-20 05:30AM  
Jun-15-20 05:30AM  
May-12-20 04:05PM  
May-07-20 12:08PM  
May-04-20 05:30AM  
Apr-29-20 05:30AM  
Apr-15-20 02:28PM  
Apr-08-20 04:59PM  
Mar-06-20 04:05PM  
Mar-05-20 05:30AM  
Mar-04-20 05:30AM  
Feb-28-20 02:15PM  
Feb-18-20 05:30AM  
Jan-28-20 02:56PM  
Jan-17-20 05:34AM  
Jan-03-20 02:44PM  
Jan-02-20 08:46AM  
05:30AM  
Nov-13-19 04:05PM  
Oct-19-19 08:47AM  
Oct-11-19 05:30AM  
Sep-30-19 05:30AM  
Sep-27-19 05:45AM  
05:30AM  
Sep-08-19 04:28PM  
Sep-03-19 09:18AM  
05:30AM  
Aug-14-19 03:40PM  
Aug-12-19 04:05PM  
Jul-31-19 03:01PM  
Jul-30-19 05:30AM  
Jul-19-19 05:30AM  
Jun-27-19 05:30AM  
Jun-10-19 05:30AM  
May-14-19 04:35PM  
Apr-03-19 07:21AM  
Apr-02-19 09:00AM  
Mar-28-19 04:05PM  
Jan-31-19 10:40AM  
Jan-02-19 01:15PM  
Dec-12-18 07:30AM  
Dec-05-18 10:35AM  
Dec-04-18 12:30PM  
Nov-26-18 10:04AM  
Nov-21-18 07:35AM  
Nov-13-18 07:30AM  
Nov-07-18 07:30AM  
Sep-26-18 08:30AM  
Sep-24-18 07:00AM  
Aug-13-18 07:31PM  
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HAMILTON JOHN FDirectorJul 27Buy4.872,0009,7402,000Jul 27 09:37 PM
Truong VuCEOJul 27Buy5.115,00025,550737,353Jul 27 09:36 PM
Patzer EricDirectorJul 27Buy4.845,17525,047702,132Jul 27 09:35 PM